TW
Indivior PLC Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SUBOXONE® (buprenorphine/naloxone) Sublingual Film | Opioid Use Disorder (OUD) Maintenance Treatment | Approved |
| SUBLOCADE® (buprenorphine extended-release) Injection | Opioid Use Disorder (OUD) Maintenance Treatment | Approved |
| PERSERIS® (risperidone) Extended-Release Injection | Schizophrenia in adults | Approved |
| RBP-6000 (buprenorphine depot) | Opioid Use Disorder (OUD) | Approved |
| RBP-7000 (risperidone depot) | Schizophrenia | Approved |
| INDV-2000 | Opioid Use Disorder (OUD) | Pre-clinical |
| Digital Therapeutics (reSET®, reSET-O®) | Substance Use Disorder | Commercial |
Leadership Team at Indivior PLC
MC
Mark Crossley
Chief Executive Officer (CEO)
CH
Christian Heidbreder, Ph.D.
Chief Scientific Officer (CSO)
R(
Robert (Bob) Radie
Executive Chairman of the Board
RP
Ryan Preblick
Chief Financial Officer (CFO)
CK
Christiane Kuehne
Chief Operating Officer (COO)
SC
Shawn C. Tomasello
Chief Commercial Officer (CCO)
GJ
Guy J. (Buddy) Tucker
Senior Vice President, North America
N(
Nicolas (Nick) O'Leary
Senior Vice President, General Counsel & Company Secretary
S(
Santiago (Yago) de la Serna
Senior Vice President, Global Head of Human Resources
DT
David Tejada
Senior Vice President, Global Head of Corporate Affairs & Investor Relations